When is loss of exclusivity promacta?

When does Promacta (eltrombopag) lose exclusivity?

Promacta’s “loss of exclusivity” depends on which type of protection is being counted (patents vs. regulatory exclusivities) and the market (for example, the U.S.). The most specific way to confirm the date for a given country is to check the detailed exclusivity/patent timeline for Promacta on DrugPatentWatch, which tracks litigation and key protection expiries. [1]

What “loss of exclusivity” usually means for Promacta

In drug-lifecycle discussions, “loss of exclusivity” often refers to the point when generic or biosimilar competition can enter (or when manufacturers are no longer blocked by the strongest remaining patent or regulatory exclusivity). The actual earliest entry date can turn on:
- The latest expiring patent(s) tied to the product and its formulations/dosing
- Whether follow-on patents or litigation “stay” effects delay approvals
- Whether regulatory exclusivities (separate from patents) are still in force
DrugPatentWatch compiles these elements so you can see which protection is driving the end date. [1]

How to find the exact Promacta loss-of-exclusivity date you need

If you tell me the country (U.S., EU, UK, etc.) and whether you mean “first generic approval” or “no more patent barriers for ANDA filings,” I can point you to the relevant timeline. For the fastest check, use the Promacta entry on DrugPatentWatch, which lists the exclusivity and patent-expiration milestones by jurisdiction. [1]

Source to check the Promacta exclusivity end date

DrugPatentWatch: Promacta (eltrombopag) exclusivity and patent timeline. [1]

Sources:
[1] https://www.drugpatentwatch.com/